Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT05915286
PHASE4

Diuretic Use in Hemodialysis Patients With Residual Renal Function

Sponsor: University of Alberta

View on ClinicalTrials.gov

Summary

This pilot trial will evaluate the use of diuretic medications (furosemide and chlorthalidone) in participants on dialysis to see if these medications work to preserve existing kidney function, increase urine output, and reduce weight gain between dialysis treatments. Diuretics, which are sometimes called water pills, help the body to get rid of salt (sodium) and water. There are currently no guidelines for the use of diuretic medications in dialysis patients, including the type to use, or how much to use.

Official title: Diuretic Use in Hemodialysis Patients With Residual Renal Function: a Proof of Concept Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

2

Start Date

2023-05-29

Completion Date

2025-02-21

Last Updated

2026-05-08

Healthy Volunteers

No

Interventions

DRUG

Furosemide

Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.

DRUG

Chlorthalidone

Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.

Locations (1)

University of Alberta

Edmonton, Alberta, Canada